Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mirati Therapeutics, Inc. - Common Stock (NQ:MRTX)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mirati Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
EnerSys To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Analyst Expectations For Mirati Therapeutics's Future
Via Benzinga
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
What 11 Analyst Ratings Have To Say About Mirati Therapeutics
Via Benzinga
3 Resilient Stocks with Massive Potential to Boost Your Wealth
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life. 
Via InvestorPlace
These Three Biotech Stocks Are Trading At A Discount
Investors exposed to the biotech sector have seen mixed results this year. 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
3 Biotech Stocks That Could Boom or Bust by 2025
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday. 
Via InvestorPlace
MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
From Kahn Swick & Foti, LLC
Via Business Wire
3 No-Brainer Stocks to Buy With $500 Right Now
A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts. 
Via The Motley Fool
Appian To Rally Around 47%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
Is MIRATI THERAPEUTICS INC Ready to Break Out of Its Range?
Investors are keeping a close eye on MIRATI THERAPEUTICS INC (NASDAQ:MRTX) as it boasts an impressive technical rating of 7 out of 10, signaling a possible breakout. 
Via Chartmill
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio. 
Via InvestorPlace
Opdivo's Subcutaneous Formulation Shows Promise in Advanced Kidney Cancer: Bristol Myers Squibb's Latest Findings
Bristol Myers Squibb Co (NYSE: BMY) released topline data from the Phase 3 CheckMate -67T noninferiority trial of a subcutaneous Opdivo (nivolumab) compared to intravenous (IV) Opdivo for advanced or... 
Via Benzinga
Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race
Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... 
Via PressReach
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE
From Brodsky & Smith LLC
Via GlobeNewswire
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
The company has growing pipeline optionality, according to the upgrade report. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2023
Via Benzinga
Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race
Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... 
Via PressReach
MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX
From Kahn Swick & Foti, LLC
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Shares of Tango Therapeutics Are Dropping Monday
Another company's buyout helped drive up the price last week. This week, investors started out by selling the stock. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For October 9, 2023
Via Benzinga
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM)
From Brodsky & Smith LLC
Via GlobeNewswire
Mirati Therapeutics Snags $5.8 Billion Takeover Deal, But Shares Fall On Lowball Bid
Bristol Myers Squibb hopes to buy Mirati Therapeutics for up to $5.8 billion. 
Via Investor's Business Daily
Bristol Myers Squibb Strengthens Oncology Portfolio With Mirati Therapeutics' $5B Deal
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire Mirati Therapeutics Inc (NASDAQ: MRTX) for $58.00 per share in cash, for a total  
Via Benzinga
S&P 500, Nasdaq Set For Bleak Start To Week As Middle East Tensions Dampen Risk-On Mood: Earnings, Inflation Data In Focus
Trading in stock futures suggests a lower open on Monday as traders digest the ramification of the conflict in the Middle East. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures traded lower this morning on Monday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.